Verity Asset Management’s GSK GSK Stock Holding History

Verity Asset Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.31M	Buy	25,025 +295	+1%	+$15.6K	0.5%	60
2026 Q1	$1.36M	Buy	24,730 +1,586	+7%	+$85.9K	0.57%	57
2025 Q4	$1.13M	Buy	23,144 +2,567	+12%	+$120K	0.49%	61
2025 Q3	$888K	Buy	20,577 +2,482	+14%	+$97K	0.29%	88
2025 Q2	$695K	Buy	18,095 +1,151	+7%	+$44K	0.33%	77
2025 Q1	$656K	Buy	16,944 +524	+3%	+$19.2K	0.27%	105
2024 Q4	$545K	Buy	16,420 +2,813	+21%	+$101K	0.31%	79
2024 Q3	$556K	Buy	13,607 +4,120	+43%	+$169K	0.21%	102
2024 Q2	$365K	Buy	9,487 +288	+3%	+$12.1K	0.14%	127
2024 Q1	$394K	Hold	9,199	–	–	0.22%	118
2023 Q4	$341K	Buy	9,199 +916	+11%	+$32.9K	0.22%	120
2023 Q3	$300K	Buy	+8,283	New	+$294K	0.22%	119

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Verity Asset Management's GSK Position: Q2 2026 in Review

Verity Asset Management increased its GSK (GSK) stake by 1.2% in Q2 2026, buying an estimated $15.6K and bringing the position to 25,025 shares worth $1.31M. The position accounts for 0.5% of the portfolio, ranked #60.

Verity Asset Management first reported a position in GSK in Q3 2023 and has held it in 12 quarters since. The position peaked at $1.36M in Q1 2026. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Verity Asset Management held 25,025 shares of GSK worth $1.31M as of Q2 2026.
Verity Asset Management bought 295 GSK shares in Q2 2026, an estimated $15.6K.
GSK made up 0.5% of Verity Asset Management's portfolio in Q2 2026, its #60 holding.
Verity Asset Management first reported a position in GSK in Q3 2023 and has held it in 12 quarters since.
Verity Asset Management's GSK position peaked at $1.36M in Q1 2026.
1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Verity Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.